Peptides DB
Research-centric peptide and protocol reference hub

Goserelin record · updated 6h ago

Healing & recoveryMetabolic & appetiteGrade A · human clinicalResearch use only
All 24 studiesJump to the evidenceCompare
What is Goserelin used for?

Research peptide discovered via AI researcher. peptide-based therapeutic

How it works: GnRH agonist

Primarily researched for · Healing & recoveryRoute · Subcutaneous injection

Development stage

where Goserelin sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 90 registered trials. It describes the research record, not a recommendation.

Identity
NameGoserelin
Chain length—
Molecular weight1,269.4 Da
FormulaC59H84N18O14
Structure typeNot established
ClassHealing
Research levelFDA Approved
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 5311128. No verified residue count for this compound.

Pharmacology
MechanismGnRH agonist
RouteSubcutaneous injection
Half-life~2–4 hours
Time to peak1–2 hours
Duration~28 days
Extraction confidence0.90
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 8, 2026. How this works →
Research stats
Total studies24
Human / animal / cellular17 / 1 / 1
Highest trial phasePhase 4
Years covered2009–2026
Latest study14d ago
Publication history
20092026
Research funding
23 NIH projects · $6.4M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports4,091
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

24 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Assessing the Feasibility of a Self-Management Intervention for Individuals With Advanced Prostate Cancer and Comorbid Type II Diabetes Mellitus.
Finding> 75% engagement and average acceptability score of 37.3/56.
Human2026Full text read0.80
From Treatment Discontinuation to Aggressive Recurrence: A Cautionary Case Report of Rapid Progression to Invasive Carcinoma Following Torimifene-Induced Hepatotoxicity and Drug Withdrawal in a Patient With Completely Resected Intraductal Papillary Carcinoma.
TakeawayDiscontinuation of adjuvant endocrine therapy due to toxicity can lead to rapid cancer progression, underscoring the need for careful management and monitoring.
Human2026Full text read0.70
Impact of leuprolide and goserelin on androgen suppression and adverse events in patients with prostate cancer.
FindingNot reported in abstract.
Human2026Full text read0.80
Drug-associated pancreatic cancer: insights from real-world pharmacovigilance and network pharmacology.
FindingMedian weight for GLP-1 analogues was 91 kg, and for compound hypoglycemic agents was 82 kg, p < 0.01.
review2025Full text read0.80
Clinical pathological changes in prostate cancer patients after hormonal therapy: A single-center pilot study.
FindingCorrected mean AUC was 0.725 (95% CI: 0.58-0.87).
Human2026Full text read0.80
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial.
FindingMedian PFS not reached vs 20.2 months with placebo, HR 0.55, 95% CI 0.38-0.77, 1-sided P < .001.
Human2026Full text read0.90
Understanding risk perception and risk-reducing decision-making for surgery among individuals with a genetic predisposition to epithelial ovarian cancer.
Finding63 surveys and 20 interviews completed.
Human2026Full text read0.80
Efficacy and safety of goserelin vs. leuprolide in premenopausal breast cancer patients receiving adjuvant endocrine therapy: A retrospective cohort study.
Finding88.89% of leuprolide patients achieved substantial estrogen reduction vs 92.78% of goserelin patients, RD = -3.89%, 95% CI: -12.18% to 4.40%; p = 0.354.
Human2023Full text read0.80
Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy.
FindingNot reported in abstract.
Animal2009Full text read0.70
Darolutamide Alone and in Combination With Goserelin in Androgen Receptor-Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial.
FindingConfirmed ORR of 45.2% (90% CI, 29.7 to 61.3) in the combination cohort, n=33.
Human2023Full text read0.80
Exceptional Response to Short-course 177 Lu-PSMA Radioligand Therapy in a Patient With Metastatic Hormone-sensitive Prostate Cancer.
FindingPSA reduced from 433.75 ng/mL to 0.15 ng/mL after treatment.
Human2023Full text read0.80
Impact of Lifestyle Patterns on Breast Cancer Prognosis: Evidence from a UK Biobank Survival Study
Finding3-year AUC = 0.72 for breast cancer survival prediction.
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Goserelin will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Goserelin is discussed should be drawn from it.